She was enrolled in a phase 1–2 clinical trial which evaluated the safety, tolerability, pharmacokinetics, and antitumor activity of zorifertinib in Chinese patients with EGFR‐mutant NSCLC and BM (NCT03360929) on July 12, 2018. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.